University of Washington and Seattle biotech win $245M patent judgment against Guardant

TwinStrand graphic A federal judge has entered a final judgment requiring Guardant Health to pay more than $245 million to Seattle biotech TwinStrand Biosciences and the University of Washington over DNA sequencing technology developed at the university. The judgment, entered Friday in U.S. District Court in Delaware, follows a 2023 jury verdict...